-
Je něco špatně v tomto záznamu ?
Emerging Technologies for Pulmonary Vein Isolation
FD. Ramirez, VY. Reddy, R. Viswanathan, M. Hocini, P. Jaïs
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Free Medical Journals
od 1953 do Před 1 rokem
Freely Accessible Science Journals
od 1953 do Před 1 rokem
Open Access Digital Library
od 1953-01-01
Open Access Digital Library
od 1953-01-01
- MeSH
- fibrilace síní chirurgie MeSH
- katetrizační ablace metody MeSH
- lidé MeSH
- venae pulmonales chirurgie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with considerable morbidity and mortality. Electrically isolating the pulmonary veins from the left atrium by catheter ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its success varies depending on multiple factors, including arrhythmic burden. Although procedural outcomes have improved over the years, further gains are limited by a seemingly zero-sum relationship between effectiveness and safety, which is largely a product of the available technologies. Current energies used to create contiguous, transmural, and durable atrial lesions can result in serious complications if they reach the esophagus or phrenic nerve, for instance-structures that can be adjacent to the atrial myocardium, often within millimeters of the energy source. Consequently, high rates of pulmonary vein-left atrium reconnections are consistently seen in clinical studies and in clinical practice as operators appropriately forgo ablation effectiveness to protect patients from harm. However, as ablative technologies evolve to circumvent this stalemate, safer, and more effective pulmonary vein isolation seems increasingly realistic. Furthermore, the innovative nature of these technologies raises the prospect of markedly improved procedural efficiency, which could increase patient comfort, reduce operator occupational injuries, and enhance the use of health resources-all of which are increasingly important considerations particularly as the demand for catheter ablation for atrial fibrillation continues to rise. We herein review 3 promising candidate ablation technologies with the potential to revolutionize the management of patients with atrial fibrillation: electroporation (pulsed-field ablation), expandable lattice-tip radiofrequency ablation/electroporation, and ultra-low temperature cryoablation.
From the University of Bordeaux CHU Bordeaux Bordeaux Pessac France
Helmsley Electrophysiology Center Icahn School of Medicine at Mount Sinai New York NY
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020447
- 003
- CZ-PrNML
- 005
- 20210830102128.0
- 007
- ta
- 008
- 210728s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/CIRCRESAHA.120.316402 $2 doi
- 035 __
- $a (PubMed)32716722
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ramirez, F Daniel $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
- 245 10
- $a Emerging Technologies for Pulmonary Vein Isolation / $c FD. Ramirez, VY. Reddy, R. Viswanathan, M. Hocini, P. Jaïs
- 520 9_
- $a Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with considerable morbidity and mortality. Electrically isolating the pulmonary veins from the left atrium by catheter ablation is superior to antiarrhythmic drug therapy for maintaining sinus rhythm, but its success varies depending on multiple factors, including arrhythmic burden. Although procedural outcomes have improved over the years, further gains are limited by a seemingly zero-sum relationship between effectiveness and safety, which is largely a product of the available technologies. Current energies used to create contiguous, transmural, and durable atrial lesions can result in serious complications if they reach the esophagus or phrenic nerve, for instance-structures that can be adjacent to the atrial myocardium, often within millimeters of the energy source. Consequently, high rates of pulmonary vein-left atrium reconnections are consistently seen in clinical studies and in clinical practice as operators appropriately forgo ablation effectiveness to protect patients from harm. However, as ablative technologies evolve to circumvent this stalemate, safer, and more effective pulmonary vein isolation seems increasingly realistic. Furthermore, the innovative nature of these technologies raises the prospect of markedly improved procedural efficiency, which could increase patient comfort, reduce operator occupational injuries, and enhance the use of health resources-all of which are increasingly important considerations particularly as the demand for catheter ablation for atrial fibrillation continues to rise. We herein review 3 promising candidate ablation technologies with the potential to revolutionize the management of patients with atrial fibrillation: electroporation (pulsed-field ablation), expandable lattice-tip radiofrequency ablation/electroporation, and ultra-low temperature cryoablation.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a fibrilace síní $x chirurgie $7 D001281
- 650 _2
- $a katetrizační ablace $x metody $7 D017115
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a venae pulmonales $x chirurgie $7 D011667
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Reddy, Vivek Y $u Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (V.Y.R.) $u Homolka Hospital, Prague, Czech Republic (V.Y.R.)
- 700 1_
- $a Viswanathan, Raju $u Farapulse, Inc, Menlo Park, CA (R.V.)
- 700 1_
- $a Hocini, Mélèze $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
- 700 1_
- $a Jaïs, Pierre $u From the University of Bordeaux, CHU Bordeaux, Bordeaux-Pessac, France (F.D.R., M.H., P.J.) $u IHU LIRYC ANR-10-IAHU-04, Equipex MUSIC ANR-11-EQPX-0030 (F.D.R., M.H., P.J.)
- 773 0_
- $w MED00001092 $t Circulation research $x 1524-4571 $g Roč. 127, č. 1 (2020), s. 170-183
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32716722 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102128 $b ABA008
- 999 __
- $a ok $b bmc $g 1691091 $s 1140893
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 127 $c 1 $d 170-183 $e 20200618 $i 1524-4571 $m Circulation research $n Circ Res $x MED00001092
- LZP __
- $a Pubmed-20210728